^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMM27M

    i
    Other names: IMM27M, SYN-27M, IMM-27M, IMM 27M, SYN27M, SYN 27M, AXN-27M
    Associations

    News

    Trials
    Company:
    ImmuneOnco Biopharma
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=108, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
    New P1 trial
    |
    IMM27M
    over2years
    Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=16, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting --> Recruiting | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Apr 2023 --> Aug 2023
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    IMM27M